The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Open accessAbstract
BACKGROUND: Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption. METHODS: We enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and randomly assigned them in a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) in a blinded fashion for 12 months, followed by open-label alendronate in both groups. The primary end points were the cumulative incidence of new vertebral fracture at 24 months and the cumulative incidence of clinical fracture (nonvertebral and symptomatic vertebral fracture) at the time of the primary analysis (after clinical fractures had been confirmed in ≥330 patients). Secondary end points included the incidences of nonvertebral and hip fracture at the time of the primary analysis. Serious cardiovascular adverse events, osteonecrosis of the jaw, and atypical femoral fractures were adjudicated. RESULTS: Over a period of 24 months, a 48% lower risk of new vertebral fractures was observed in the romosozumab-to-alendronate group (6.2% [127 of 2046 patients]) than in the alendronate-to-alendronate group (11.9% [243 of 2047 patients]) (P<0.001). Clinical fractures occurred in 198 of 2046 patients (9.7%) in the romosozumab-to-alendronate group versus 266 of 2047 patients (13.0%) in the alendronate-to-alendronate group, representing a 27% lower risk with romosozumab (P<0.001). The risk of nonvertebral fractures was lower by 19% in the romosozumab-to-alendronate group than in the alendronate-to-alendronate group (178 of 2046 patients [8.7%] vs. 217 of 2047 patients [10.6%]; P=0.04), and the risk of hip fracture was lower by 38% (41 of 2046 patients [2.0%] vs. 66 of 2047 patients [3.2%]; P=0.02). Overall adverse events and serious adverse events were balanced between the two groups. During year 1, positively adjudicated serious cardiovascular adverse events were observed more often with romosozumab than with alendronate (50 of 2040 patients [2.5%] vs. 38 of 2014 patients [1.9%]). During the open-label alendronate period, adjudicated events of osteonecrosis of the jaw (1 event each in the romosozumab-to-alendronate and alendronate-to-alendronate groups) and atypical femoral fracture (2 events and 4 events, respectively) were observed. CONCLUSIONS: In postmenopausal women with osteoporosis who were at high risk for fracture, romosozumab treatment for 12 months followed by alendronate resulted in a significantly lower risk of fracture than alendronate alone. (Funded by Amgen and others; ARCH ClinicalTrials.gov number, NCT01631214 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, major cardiac events were observed in the ARCH study, while headaches, arthralgia, and injection site reactions were also observed [89,90].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As of 2021, it has reached Phase III trials, which have shown an increase in bone mineral density and a decrease in vertebral and hip fractures.”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“The ARCH study showed a 48% lower risk of new vertebral fractures in the group that received romosozumab and alendronate than in the alendronate-only group [89].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Epidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationRomosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Self-citationBrunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,000
Diagnosis and Management of Osteoporosis: A Comprehensive Review of Guidelines
Rentzeperi, E., Pegiou, S., Tsakiridis, I. G., Kalogiannidis, I. A., Kourtis, A., Mamopoulos, A. M., Athanasiadis, A. P., & Dagklis, T. (2023) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001181 · Cited by 39
Practical guidance for the use of bisphosphonates in osteoporosis
Compston, J. E. (2020) · Bone · doi:10.1016/j.bone.2020.115330 · Cited by 42
Roles of bone-derived hormones in type 2 diabetes and cardiovascular pathophysiology
Lin, X., Onda, D.-A., Yang, C.-H., Lewis, J. R., Levinger, I., & Loh, K. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101040 · Cited by 39
Injectable Hydrogels as Three-Dimensional Network Reservoirs for Osteoporosis Treatment
Zheng, Z., Yu, C., & Wei, H. (2020) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2020.0168 · Cited by 39
Osteoporotic fractures of the thoracic and lumbar vertebrae: diagnosis and conservative treatment
Spiegl, U. J. A., Bork, H., Grüninger, S., Maus, U. M., Osterhoff, G., Scheyerer, M. J., Pieroh, P., Schnoor, J., Heyde, C., & Schnake, K. J. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0295 · Cited by 40
Simpson, C. R., Kelly, H. M., & Murphy, C. M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.011 · Cited by 38
Söreskog, E., Lindberg, I., Kanis, J. А., Åkesson, K., Willems, D., Lorentzon, M., Ström, O., Berling, P., & Borgström, F. (2021) · Osteoporosis International · doi:10.1007/s00198-020-05780-8 · Cited by 38
Self-citationEvenepoel, P., Cunningham, J., Ferrari, S., Haarhaus, M. L., Javaid, M. K., Lafage‐Proust, M., Prieto‐Alhambra, D., Torres, P. U., Cannata-Andía, J. B., workgroup, O. B. O. T. E. R. O. (., et al. (2021) · Osteoporosis International · doi:10.1007/s00198-021-05975-7 · Cited by 38
Johansson, L., Johansson, H., Axelsson, K. F., Litsne, H., Harvey, N. C., Liu, E., Leslie, W. D., Vandenput, L., McCloskey, E. V., Kanis, J. A., et al. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06387-x · Cited by 39
Self-citationRegulation of bone homeostasis by MERTK and TYRO3
Engelmann, J., Zarrer, J., Gensch, V., Riecken, K., Berenbrok, N., Luu, T. V., Beitzen‐Heineke, A., Vargas-Delgado, M. E., Pantel, K., Bokemeyer, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33938-x · Cited by 38
Osteoporosis: molecular pathogenesis and therapeutic interventions
Zhang, X., Liang, Y., Zhang, F., & Liu, X. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00349-5 · Cited by 37
Seeto, A. H., Abrahamsen, B., Ebeling, P. R., & Rodríguez, A. J. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4157 · Cited by 36
Kobayakawa, T., Miyazaki, A., Kanayama, Y., Hirano, Y., Takahashi, J. A., Suzuki, T., & Nakamura, Y. (2022) · Modern Rheumatology · doi:10.1093/mr/roac014 · Cited by 36
Review of the guideline of the American College of Physicians on the treatment of osteoporosis
Kanis, J. А., Cooper, C. C., Rizzoli, R., & Reginster, J.-Y. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4504-y · Cited by 36
Osteoporosis, densidad mineral ósea y complejo CKD-MBD (II): implicaciones terapéuticas
Bover, J., Ureña, P., Láiz, A. M., Torregrosa, J., Rodríguez-García, M., Castro-Alonso, C., Górriz, J. L., Benito, S., López‐Báez, V., Cora, M. J. L., et al. (2019) · Nefrología · doi:10.1016/j.nefro.2018.10.009 · Cited by 37
Tang, W., Ding, Z., Gao, H., Yan, Q., Liu, J., Han, Y., Hou, X., Liu, Z., Chen, L., Yang, D., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.07.001 · Cited by 35
Shakeri, A., & Adanty, C. (2020) · Journal of Population Therapeutics & Clinical Pharmacology · doi:10.15586/jptcp.v27i1.655 · Cited by 35
Closing the gap in osteoporosis management: the critical role of primary care in bone health
Singer, A. J., Sharma, A. K., Deignan, C., & Borgermans, L. A. D. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2141483 · Cited by 36
Kumar, S., Gild, M. L., McDonald, M. M., Kim, A. S., Clifton-Bligh, R. J., & Girgis, C. M. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07139-9 · Cited by 36
Cheng, S., Chu, W., Chou, W.-H., Chu, W., & Kang, Y. (2024) · Drug Safety · doi:10.1007/s40264-024-01475-9 · Cited by 35
Denosumab for the treatment of osteoporosis
McClung, M. R. (2017) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2017.01.002 · Cited by 36
Elias, R. M., Dalboni, M. A., Coelho, A. C. E., & Moysés, R. M. A. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0486-0 · Cited by 35
Romosozumab: a novel bone anabolic treatment option for osteoporosis?
Kerschan‐Schindl, K. (2019) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-019-00721-5 · Cited by 35
Evaluation and Management of Osteoporosis and Sarcopenia in Patients with Distal Radius Fractures
Shah, G. M., Gong, H. S., Chae, Y. J., Kim, Y. S., Kim, J., & Baek, G. H. (2020) · Clinics in Orthopedic Surgery · doi:10.4055/cios.2020.12.1.9 · Cited by 35
Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis
Prather, C., Adams, E. N., & Zentgraf, W. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa285 · Cited by 35
Osteoporosis in Frail Older Adults: Recommendations for Research from the ICFSR Task Force 2020
Rolland, Y., Cesari, M., Fielding, R. A., Reginster, J., Vellas, B. J., & Cruz-Jentoft, A. J. (2021) · The Journal of Frailty & Aging · doi:10.14283/jfa.2021.4 · Cited by 36
Javaid, M. K. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01844-9 · Cited by 35
The effect of parathyroid hormone on osteogenesis is mediated partly by osteolectin
Zhang, J., Cohen, A., Shen, B., Du, L., Tasdogan, A., Zhao, Z., Shane, E. J., & Morrison, S. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026176118 · Cited by 35
Hernández, A. V., Pérez-López, F. R., Piscoya, A., Pasupuleti, V., Roman, Y. M., Thota, P., & Herrera, A. (2019) · Maturitas · doi:10.1016/j.maturitas.2019.08.003 · Cited by 35
Gani, L. U., Sritara, C., Blank, R. D., Chen, W., Gilmour, J., Dhaliwal, R., & Gill, R. S. (2023) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2023.101440 · Cited by 34
Vilaça, T., Schini, M., Lui, L., Ewing, S. K., Thompson, A. R., Vittinghoff, E., Bauer, D. C., Eastell, R., Black, D. M., & Bouxsein, M. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae126 · Cited by 35
Bhattacharyya, S., Pal, S., & Chattopadhyay, N. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.02.028 · Cited by 34
Anabolic agents: what is beyond osteoporosis?
Liu, Y., Levack, A. E., Marty, E., Or, O., Samuels, B., Redko, M., & Lane, J. M. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4507-8 · Cited by 34
Leto, G., D’Onofrio, L., Lucantoni, F., Zampetti, S., Campagna, G., Foffi, C., Moretti, C., Carlone, A., Palermo, A., Leopizzi, M., et al. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3069 · Cited by 34
Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk
Lim, S. Y. (2022) · Women s Health · doi:10.1177/17455057221125577 · Cited by 37
Novel insights on the effect of sclerostin on bone and other organs
Dreyer, T. J., Keen, J. A. C., Wells, L. M., & Roberts, S. J. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0209 · Cited by 36
Muraca, M., & Cappariello, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228682 · Cited by 35
Kobayashi, T., Morimoto, T., Ito, K., Mawatari, M., & Shimazaki, T. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07118-0 · Cited by 33
Effect of uremic toxin-indoxyl sulfate on the skeletal system
Liu, W.-C., Wu, C., Lim, P., Chien, S.-W., Hou, Y., Zheng, C., Shyu, J., Lin, Y., & Lu, K. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.05.057 · Cited by 33
Yang, Y. J., Yu, T., Tang, H., Ren, Z., Li, Q., Jia, J., Chen, H., Fu, J., Ding, S., Hao, Q., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00731 · Cited by 33
Paton‐Hough, J., Tazzyman, S. J., Evans, H., Lath, D., Down, J. M., Green, A. C., Snowden, J. A., Chantry, A., & Lawson, M. A. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3606 · Cited by 34
SEIOMM Working Group, Guañabens, N., Moro-Álvarez, M. J., Casado, E., Blanch‐Rubió, J., Gómez‐Alonso, C., Diaz‐Guerra, G. M., del Pino‐Montes, J., Valero, C., Peris, P., et al. (2019) · Endocrine · doi:10.1007/s12020-019-01919-8 · Cited by 33
Carpenter, K. A., & Ross, R. D. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3923 · Cited by 33
Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis
Saag, K. G., Petersen, J., & Grauer, A. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1714810 · Cited by 33
Self-citationBone Loss after Solid Organ Transplantation: A Review of Organ-Specific Considerations
Kim, K. J., Ha, J., Kim, S. W., Kim, J., Lee, S., Choi, H. S., Hong, N., Kong, S. H., Ahn, S. H., Park, S. Y., et al. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1939 · Cited by 32
Masuda, S., Fukasawa, T., Matsuda, S., Yoshida, S., & Kawakami, K. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07255-6 · Cited by 32
Romosozumab for the treatment of osteoporosis – a systematic review
Mäkinen, V.-N., Sølling, A. S., McClung, M. R., & Langdahl, B. L. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02469-1 · Cited by 32
Long-term treatment strategies for postmenopausal osteoporosis
Cosman, F. (2018) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000509 · Cited by 33
Genetic approaches to metabolic bone diseases
Hannan, F. M., Newey, P. J., Whyte, M. P., & Thakker, R. V. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13803 · Cited by 32
Rodríguez, A. J., Ernst, M., Nybo, M., Prieto‐Alhambra, D., Ebeling, P. R., Hermann, A. P., & Abrahamsen, B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa481 · Cited by 32
Holdsworth, G., Staley, J. R., Hall, P., van Koeverden, I. D., Vangjeli, C., Okoye, R., Boyce, R. W., Turk, J. R., Armstrong, M., Wolfreys, A., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4287 · Cited by 32
Ebina, K., Etani, Y., Tsuboi, H., Nagayama, Y., Kashii, M., Miyama, A., Kunugiza, Y., Hirao, M., Okamura, G., Noguchi, T., et al. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06386-y · Cited by 32
Chandran, M. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000564 · Cited by 34
Lau, E. M. C., Dinavahi, R. V., Woo, Y. C., Wu, C., Guan, J., Maddox, J., Tolman, C., Yang, W., & Shin, C. S. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05324-0 · Cited by 32
Self-citationCurrent therapeutic approach of chronic kidney disease‐mineral and bone disorder
Zaimi, M., & Grapsa, E. (2024) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.14177 · Cited by 31
Fontalis, A., Kenanidis, E. I., Kotronias, R. A., Papachristou, A., Anagnostis, P. G., Potoupnis, M. E., & Tsiridis, E. E. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1594772 · Cited by 31
Management of comorbidities in haemophilia
Kempton, C. L., Makris, M., & Holme, P. A. (2020) · Haemophilia · doi:10.1111/hae.14013 · Cited by 31
Hara, T., Hijikata, Y., Matsubara, Y., & Watanabe, N. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013424.pub2 · Cited by 31
Tian, A., Jia, H., Zhu, S., Lü, B., Li, Y., Ma, J., & Ma, X. (2021) · Orthopaedic Surgery · doi:10.1111/os.13136 · Cited by 31
Riancho, J. A., Peris, P., González-Macı́as, J., & Pérez‐Castrillón, J. L. (2022) · Revista Clínica Española · doi:10.1016/j.rce.2021.12.007 · Cited by 31
PHARMACOLOGICAL MANAGEMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN: THE CURRENT STATE OF THE ART
Gatti, D., & Fassio, A. (2019) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.15586/jptcp.v26i4.646 · Cited by 31
Effects of diabetes on osteocytes
Kaur, J., Khosla, S., & Farr, J. N. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000733 · Cited by 32
Treating osteoporosis: risks and management
Zhu, J., & MARCH, L. M. (2022) · Australian Prescriber · doi:10.18773/austprescr.2022.054 · Cited by 31
Hadaya, D., Gkouveris, I., Soundia, A., Bezouglaia, O., Boyce, R. W., Stolina, M., Dwyer, D., Dry, S., Pirih, F. Q. M., Aghaloo, T. L., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3581 · Cited by 31
Bliuc, D., Tran, T. S., van Geel, T. A. C. M., Adachi, J. D., Berger, C., van den Bergh, J. P., Eisman, J. A., Geusens, P., Goltzman, D., Hanley, D. A., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3816 · Cited by 30
Lin, S., Hung, M.-C., Chang, S., Tsuang, F.-Y., Chang, J. Z., & Sun, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143043 · Cited by 30
Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density
Poole, K. E. S., Treece, G. M., Pearson, R. A., Gee, A. H., Bolognese, M. A., Brown, J. P., Goemaere, S., Grauer, A., Hanley, D. A., Mautalén, C., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4465 · Cited by 30
Self-citationTakashi, Y., & Kawanami, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042376 · Cited by 30
Effective Communication and the Osteoporosis Care Gap
Ralston, K. A. P., Hauser, B., Paskins, Z., & Ralston, S. H. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4701 · Cited by 30
Seeto, A. H., Tadrous, M., Gebre, A. K., Lewis, J. R., Fink, H. A., Ebeling, P. R., & Rodríguez, A. J. (2022) · Bone · doi:10.1016/j.bone.2022.116610 · Cited by 31
Riancho, J., Peris, P., González-Macı́as, J., & Pérez-Castrillón, J.-L. (2022) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.4321/s1889-836x2022000100003 · Cited by 36
Management of bone loss due to endocrine therapy during cancer treatment
Khan, M. I. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06672-3 · Cited by 30
Reversal of the diabetic bone signature with anabolic therapies in mice
Marino, S., Akel, N. S., Li, S., Cregor, M. D., Jones, M., Perez, B., Troncoso, G., Meeks, J., Stewart, S., Sato, A. Y., et al. (2023) · Bone Research · doi:10.1038/s41413-023-00261-0 · Cited by 30
Everts‐Graber, J., Wenger, M., Oser, S., Studer, U., Steiner, C., Ziswiler, H., Sromek, K., Schmid, G., Gahl, B., Häuselmann, H., et al. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07155-9 · Cited by 29
Cosman, F., Oates, M. K., Betah, D., Timoshanko, J., Wang, Z., Ferrari, S., & McClung, M. R. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae116 · Cited by 29
Patel, D., & Saxena, B. (2024) · Journal of Orthopaedic Reports · doi:10.1016/j.jorep.2024.100472 · Cited by 29
Kobayakawa, T., Miyazaki, A., Takahashi, J. A., & Nakamura, Y. (2022) · Bone · doi:10.1016/j.bone.2022.116480 · Cited by 30
Schnurri-3 inhibition suppresses bone and joint damage in models of rheumatoid arthritis
Stavre, Z., Kim, J., Yang, Y.-S., Nündel, K., Chaugule, S. R., Sato, T., Park, K. H., Gao, G., Gravallese, E. M., & Shim, J. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2218019120 · Cited by 29
Dzobo, K., Thomford, N. E., & Senthebane, D. A. (2019) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2019.0147 · Cited by 29
Fatima, N., Massaad, E., Hadzipasic, M., Shankar, G. M., & Shin, J. H. (2020) · Neurosurgical Review · doi:10.1007/s10143-020-01359-3 · Cited by 29
Mechanisms Underlying Medication‐Related Osteonecrosis of the Jaw
Lee, K., Kim, K., Kim, J. Y., Kim, J., Kang, Y., Kim, Y. H., & Kim, S. (2024) · Oral Diseases · doi:10.1111/odi.15198 · Cited by 28
Wong, P. D., Chen, W., Ewald, D. P., Girgis, C. M., Rawlin, M., Tsingos, J., & Waters, J. (2025) · The Medical Journal of Australia · doi:10.5694/mja2.52637 · Cited by 30
Advances in strontium-releasing biomaterials for bone repair
Mehta, D., & Gentleman, E. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123718 · Cited by 28
Molecular understanding of pharmacological treatment of osteoporosis
Tanaka, S. (2019) · EFORT Open Reviews · doi:10.1302/2058-5241.4.180018 · Cited by 28
Sietsema, D. L. (2020) · Nursing Clinics of North America · doi:10.1016/j.cnur.2020.02.002 · Cited by 30
Baek, K., Chung, Y., Koh, J., Kim, I. J., Kim, K. M., Min, Y., Park, K. D., Dinavahi, R. V., Maddox, J., Yang, W., et al. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.848 · Cited by 28
Self-citationPapapoulos, S. E., Bone, H. G., Cosman, F., Dempster, D. W., McClung, M. R., Nakamura, T., Restrepo, J. F. M., Bouxsein, M., Cohn, D., de Papp, A., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4284 · Cited by 28
Lu, J., Hu, D., Ma, C., & Shuai, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.938447 · Cited by 29
Luo, C., Qin, S.-X., Wang, Q., Li, Y.-F., Qu, X., Yue, C., Hu, L., Sheng, Z., Wang, X.-B., & Xia, W. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01910-7 · Cited by 28
Everts‐Graber, J., Bonél, H., Lehmann, D., Gahl, B., Häuselmann, H., Studer, U., Ziswiler, H., Reichenbach, S., & Lehmann, T. (2022) · JBMR Plus · doi:10.1002/jbm4.10681 · Cited by 28
Simic, M. K., Mohanty, S. T., Xiao, Y., Cheng, T. L., Taylor, V. E., Charlat, O., Croucher, P. I., & McDonald, M. M. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4809 · Cited by 28
Boudin, E., & Hul, W. V. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.06.003 · Cited by 29
Taylor, A. D., & Saag, K. G. (2019) · Core evidence · doi:10.2147/ce.s172820 · Cited by 28
Self-citationTherapeutic strategy for atherosclerosis based on bone-vascular axis hypothesis
Kim, J., Lee, W. S., & Kim, J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107436 · Cited by 28
Serum Sclerostin, Body Composition, and Sarcopenia in Hemodialysis Patients with Diabetes
de Medeiros, M. C. W. C., Rocha, N. D. A., Bandeira, E., Dantas, I., Chaves, C., Oliveira, M., & Bandeira, F. A. F. (2020) · International Journal of Nephrology · doi:10.1155/2020/4596920 · Cited by 28
Einfluss spezifischer Osteoporosemedikamente auf die Frakturheilung
Hesse, E., Neuerburg, C., Kammerlander, C., Stumpf, U. C., Stange, R., & Böcker, W. (2019) · Der Unfallchirurg · doi:10.1007/s00113-019-0669-x · Cited by 27
Lewis, J. W., Frost, K., Neag, G., Wahid, M., Finlay, M., Northall, E., Abudu, O., Kemble, S., Davis, E. T., Powell, E., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101574 · Cited by 27
Anabolic Therapy for the Treatment of Osteoporosis in Childhood
Ward, L. M., & Rauch, F. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0434-z · Cited by 28
Bashiruddin, N. K., Hayashi, M., Nagano, M., Wu, Y. Z., Matsunaga, Y., Takagi, J., Nakashima, T., & Suga, H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012266117 · Cited by 27
Ji, H., Wang, Y., Liu, H., Liu, Y., Zhang, X., Xu, J., Li, Z., & Luo, E. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.08.050 · Cited by 27
Metadata
- Authors
- Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A.
- Affiliations
- Inserm (FR)
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-10-12
- Volume
- 377
- Issue
- 15
- Pages
- 1417-1427
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2754720807
- Cited by
- 1,544
- References
- 31
- Citations by year
- 2026: 204 · 2025: 216 · 2024: 210 · 2023: 148 · 2022: 179 · 2021: 172 · 2020: 185 · 2019: 114 · 2018: 94 · 2017: 19
- FWCI
- 123.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Gilead Sciences
- Teva Pharmaceutical Industries
- Radius Health
- Medac
- Chugai Pharmaceutical
- Amgen Canada
- UCB Pharma
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- romosozumab, alendronate, osteoporosis, fracture prevention, sclerostin inhibition, postmenopausal women, vertebral fractures, hip fracture, non-vertebral fractures, bisphosphonates, cardiovascular adverse events, osteonecrosis of the jaw, atypical femoral fractures, bone formation, bone resorption, fragility fractures, open-label extension
- MeSH terms
- Aged, Antibodies, Monoclonal, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Risk, Bone Density, Osteoporosis, Postmenopausal, Incidence, Least-Squares Analysis, Spinal Fractures, Bone Remodeling, Alendronate, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
